LEHI, UT, and SOUTH SAN FRANCISCO, CA – March 16, 2022—Lumea, the global leader in integrated digital pathology solutions and Verily, an Alphabet precision health company, today announced a strategic…
Read More
Why hasn’t Digital Pathology really taken hold, and will it ever be financially and functionally viable for routine work? Every pathologist knows we’re supposed to be entering the age of...
Read More
Alphabet’s life sciences arm, Verily, is partnering with the digital pathology platform Lumea to improve the objectivity and efficiency of prostate cancer diagnosis, prognosis and therapy selection. Verily developed AI systems for…
TruCore Pathology is a team of board-certified, expert pathologists. They use Lumea’s proprietary tissue handling technology to get larger, higher quality samples that increase cancer detection. Lumea is advancing pathology…
Matthew Leavitt, MD, just co-founded the DDx Foundation. His aim is to progress prostate cancer research and treatment through digital diagnostics. The other founders are pathologists E. David Crawford, MD…
Matthew Leavitt, MD, Lumea Founder had the opportunity to speak at Cambridge Health Institute’s 7th annual Digital Pathology Conference. This Cambridge conference focused on transforming medicine in a digital world. “Seven years…
Recent Comments